Predicted Cellularity using RNASeq-Based Cellular Deconvolution Differentiates Periprosthetic Joint Infection from Non-Infectious Arthroplasty Failure

Abstract

Listen

Translate article

Abstract Differentiation of aseptic and septic causes of arthroplasty failure is essential due to their different treatment schemes. We hypothesized that predicted cellularity profiling of sonicate fluid using the RNASeq-based the cellular deconvolution tools CIBERSORTx and ABIS-seq can differentiate between PJI and non-infected arthroplasty failure (NIAF). Profiles were created for 93 sonicate fluid samples (40 from NIAF and 53 from PJI patients) that had been subjected to RNASeq analysis. CIBERSORTx provided 22 total predicted cell types; 12 predicted cellular abundances were differentially expressed in PJI versus NIAF, including increased neutrophils, activated mast cells, and eosinophils (p≤0.0004) and decreased M0 macrophages, M2 macrophages, and Treg cells (p≤0.0001). ABIS-seq provided 17 total predicted cell types; seven predicted cellular abundances were differentially expressed in PJI versus NIAF, including increased neutrophils, Vd2 γδ T cells, and basophils (p-values of <0.0001, 0.0003, and 0.0263, respectively) and decreased nonclassical/intermediate (NC+I) monocytes, mucosal-associated invariant T (MAIT) cells, and myeloid dendritic cells (mDC) (p-values ≤0.0001). Receiver operative characteristic area under the curve (AUC) analysis identified cells types most predictive of PJI (CIBERSORTx: neutrophils [AUC = 94], activated mast cells [AUC = 93]; ABIS-seq: neutrophils [AUC = 88]) and NIAF (ABIS-seq: NC+I monocytes [AUC = 85], MAIT cells [AUC = 80], mDCs [AUC = 81]). PJI and NIAF samples were differentially clustered by principal component analysis using both tools. Overall, cellularity profiling using RNASeq-based cellular deconvolution can differentiate between PJI and NIAF sonicate fluid samples. Work supported by NIAMS (NIH R01 AR056647). CF was supported by the Mayo Clinic Graduate School of Biomedical Sciences and the Ph.D. Training Grant in Basic Immunology (NIH R25 GM055252 24).